- Home
- JMIA vs URGN Comparison
JMIA vs URGN Comparison
Compare JMIA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMIA
- URGN
- Stock Information
- Founded
- JMIA 2012
- URGN 2004
- Country
- JMIA Germany
- URGN United States
- Employees
- JMIA N/A
- URGN N/A
- Industry
- JMIA Catalog/Specialty Distribution
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- JMIA Consumer Discretionary
- URGN Health Care
- Exchange
- JMIA Nasdaq
- URGN Nasdaq
- Market Cap
- JMIA 573.4M
- URGN 547.1M
- IPO Year
- JMIA 2019
- URGN 2017
- Fundamental
- Price
- JMIA $4.56
- URGN $11.33
- Analyst Decision
- JMIA Buy
- URGN Strong Buy
- Analyst Count
- JMIA 3
- URGN 5
- Target Price
- JMIA $6.53
- URGN $44.50
- AVG Volume (30 Days)
- JMIA 4.0M
- URGN 351.4K
- Earning Date
- JMIA 11-07-2024
- URGN 11-06-2024
- Dividend Yield
- JMIA N/A
- URGN N/A
- EPS Growth
- JMIA N/A
- URGN N/A
- EPS
- JMIA N/A
- URGN N/A
- Revenue
- JMIA $181,204,000.00
- URGN $89,363,000.00
- Revenue This Year
- JMIA $3.80
- URGN $13.39
- Revenue Next Year
- JMIA $5.50
- URGN $45.06
- P/E Ratio
- JMIA N/A
- URGN N/A
- Revenue Growth
- JMIA 3.61
- URGN 15.64
- 52 Week Low
- JMIA $2.88
- URGN $10.60
- 52 Week High
- JMIA $15.04
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- JMIA 54.30
- URGN 37.97
- Support Level
- JMIA $4.22
- URGN $11.10
- Resistance Level
- JMIA $5.34
- URGN $13.13
- Average True Range (ATR)
- JMIA 0.38
- URGN 0.53
- MACD
- JMIA 0.07
- URGN -0.10
- Stochastic Oscillator
- JMIA 54.94
- URGN 12.15
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.